7 December 2023
Latham & Watkins Advises Cerevel Therapeutics in Acquisition by AbbVie
Advising firms
Deal team
24 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Charles Ruck Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Daniel Rees Lead | Latham & Watkins LLP | Partner | corporate | Orange County |
| Brian Umanoff | Latham & Watkins LLP | Associate | corporate | Not stated |
| Jack McKay | Latham & Watkins LLP | Associate | corporate | Not stated |
| AJ Blair | Latham & Watkins LLP | Associate | corporate | Not stated |
| Courtney Lem | Latham & Watkins LLP | Associate | corporate | Not stated |
| Danny Del Giorno | Latham & Watkins LLP | Associate | corporate | Not stated |
| Jacob Kempf | Latham & Watkins LLP | Associate | corporate | Not stated |
| Greg Rodgers | Latham & Watkins LLP | Partner | debt | Los Angeles |
| Ryan Gold | Latham & Watkins LLP | Associate | debt | New York |
| Jekkie Kim | Latham & Watkins LLP | Partner | intellectual property | Bay Area |
| Billy Wu | Latham & Watkins LLP | Associate | intellectual property | Bay Area |
| Katharine Moir | Latham & Watkins LLP | Partner | tax | Bay Area |
| Rasha Suleiman | Latham & Watkins LLP | Associate | tax | Bay Area |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA regulatory | Washington, D.C. |
| Trevor Thompson | Latham & Watkins LLP | Associate | FDA regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare | Bay Area |
| Maj Vaseghi | Latham & Watkins LLP | Partner | benefits | Bay Area |
| Alisa Hand | Latham & Watkins LLP | Associate | benefits | Bay Area |
| Nimra Syed | Latham & Watkins LLP | Associate | benefits | Bay Area |
| Joshua Holian | Latham & Watkins LLP | Partner | HSR | Bay Area |
| Olivia Zacks | Latham & Watkins LLP | Associate | HSR | Bay Area |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy | Bay Area |
| Mitch Bennett | Latham & Watkins LLP | Associate | data privacy | Bay Area |
Stated terms
- Stated value
- USD 8.70bn (US$8.7 billion)
- What the figure measures
- Total transaction value
- Client
- Cerevel TherapeuticsTarget
- Counterparties
- AbbVie Inc. (Buy-side)